Clinical evidence supporting cefiderocol for serious Acinetobacter baumannii infections

IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections

(2022) Alexander Lawandi et al.   CLINICAL MICROBIOLOGY AND INFECTION

Successful prolonged treatment of a carbapenem‐resistant Acinetobacter baumannii hip infection with cefiderocol: A case report

(2022) Lucia Rose et al.   PHARMACOTHERAPY

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

(2022) Marco Falcone et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program

(2022) Dee Shortridge et al.   Microbiology Spectrum

Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)

(2022) Giusy Tiseo et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Extensively drug-resistant Acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination

(2021) Noor Zaidan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii

(2021) Jacinda C. Abdul-Mutakabbir et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cefiderocol: A new cephalosporin stratagem against multidrug resistant gram-negative bacteria

(2021) Sharon Ong’uti et al.   CLINICAL INFECTIOUS DISEASES

Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis

(2021) Kimberly Cipko et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

(2021) Davide Fiore Bavaro et al.   Antibiotics-Basel

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019

(2021) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections

(2021) Pranita D Tamma et al.   CLINICAL INFECTIOUS DISEASES

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

(2021) Mical Paul et al.   CLINICAL MICROBIOLOGY AND INFECTION

All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies

(2021) Thomas P. Lodise et al.   Expert Review of Anti-Infective Therapy

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

(2020) Kenneth V.I. Rolston et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units

(2020) Alyssa R. Golden et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol

(2020) Michael Dagher et al.   Open Forum Infectious Diseases

Cefiderocol Antimicrobial Susceptibility Testing Considerations: The Achilles Heel of the Trojan Horse?

(2020) Patricia J. Simner et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients

(2020) Marco Falcone et al.   CLINICAL INFECTIOUS DISEASES

Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective

(2020) Matteo Bassetti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Cefiderocol: the Trojan horse has arrived but will Troy fall?

(2020) Emily L Heil et al.   LANCET INFECTIOUS DISEASES

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

(2020) Matteo Bassetti et al.   LANCET INFECTIOUS DISEASES

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

(2020) Richard G Wunderink et al.   LANCET INFECTIOUS DISEASES

Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively- and pan-resistant Acinetobacter baumannii

(2020) A. Oliva et al.   Journal of Global Antimicrobial Resistance

ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study

(2020) Xueliang Hua et al.   JMIR mHealth and uHealth

Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report

(2019) Enrico Maria Trecarichi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

(2018) Mical Paul et al.   LANCET INFECTIOUS DISEASES

Efficacy of Humanized Cefiderocol Exposures Over 72 hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model

(2018) Sean M Stainton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

(2018) Simon Portsmouth et al.   LANCET INFECTIOUS DISEASES

Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis

(2017) Kirati Kengkla et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Uncovering the mechanisms of Acinetobacter baumannii virulence

(2017) Christian M. Harding et al.   NATURE REVIEWS MICROBIOLOGY

Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection

(2015) Zhijin Chen et al.   Scientific Reports

Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia

(2012) H. AYDEMIR et al.   EPIDEMIOLOGY AND INFECTION

Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii

(2011) Marie Kempf et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS